Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control

Abstract

The discontinuation of omalizumab was not associated with any rebound effect or exacerbation of the disease, and control was sustained throughout the follow-up period of at least 6 months in nearly half of all patients, including all of those who had been treated for 3.5 years or more. After the reintroduction of omalizumab, 4 out of 20 patients did not respond again.

Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience

“…Treatment with omalizumab has been associated with a reduction or discontinuation of added on oral corticosteroid required for controlling asthma. 11,12,24 In our study, omalizumab treatment was also associated with a trend toward a reduction in the dose of inhaled corticosteroid, although this trend did not reach statistical significance. In a much larger prospective observational cohort study of moderate-to-severe allergic asthma, omalizumab therapy was associated with a reduction in doses of ICS, SABA, and leukotriene modifiers over 2 years in a "real-world" setting.…”

“…24 Outcomes of asthma control can be measured by assessment of current symptom scores, frequency of asthma exacerbations and oral corticosteroid usage. 25 We found that a composite symptom score of asthma control, the asthma control test (ACT) score, was significantly improved at the 16 th week of treatment in this study.…”

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives

“…Although the exact underlying mechanisms of airway remodelling still elude us, the existence of chronic persistent inflammation, involving longstanding exposure of the airways to a variety of environmental agents, cells and mediators, is generally considered a prerequisite [7][8][9], and IgE is central to the initiation and persistence of this inflammation [2,10]. Therapeutic agents with the potential to block the allergic cascade at an early stage, such as omalizumab, may potentially also attenuate airway remodelling, a possibility also supported by evidence suggesting that long-term anti-IgE treatment remains effective long after it has been discontinued [11][12][13].…”

Pilot Project «All-Russian Registry of Patients with Severe Bronchial Asthma.» The First Results in a Children’s Group of Patients (Moscow’s Observation Program)

“…Эти пациенты полу-чают преимущественно комбинированную терапию -высокие дозы ингаляционных глюкокортикостероидов и длительно действующие β2-агонисты (ДДБА), а также антагонисты лейкотриеновых рецепторов (монтелукаст), М-холинолитики (тиотропия бромид), пролонгирован-ные ксантины (теофиллин длительного действия) и ген-но-инженерные биологические препараты (монокло-нальные антитела: например, к IgE или IL5). Несмотря на хорошо согласованные и выверенные клинические рекомендации, ряд пациентов с тяжелой астмой не контролируют свою болезнь и продолжают получать системные стероиды, испытывать дневные и ночные симптомы, частые обострения, требующие госпитализа-ции и оказания медицинской помощи в условиях отделе-ния реанимации и интенсивной терапии, отмечают низ-кое качество жизни и существенно ограничены в своей повседневной активности [11,12].…”